Company Description
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally.
The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington’s disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich’s ataxia.
The company distributes its products through third-party distributors. It has collaborations with F.
Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program.
It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
| Country | United States |
| Founded | 1998 |
| IPO Date | Jun 20, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 939 |
| CEO | Matthew Klein |
Contact Details
Address: 500 Warren Corporate Center Drive Warren, New Jersey 07059 United States | |
| Phone | 908 222 7000 |
| Website | ptcbio.com |
Stock Details
| Ticker Symbol | PTCT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001070081 |
| CUSIP Number | 69366J200 |
| ISIN Number | US69366J2006 |
| Employer ID | 04-3416587 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Matthew B. Klein F.A.C.S., M.D., M.S. | Chief Executive Officer and Director |
| Dr. Allan Steven Jacobson Ph.D. | Co-Founder and Independent Director |
| Pierre Gravier M.S. | Chief Financial Officer |
| Dr. Neil Almstead Ph.D. | Chief Technical Operations Officer |
| Eric Pauwels | Chief Business Officer |
| Dr. Lee Golden M.D., Ph.D. | Executive Vice President and Chief Medical Officer |
| Christine Utter CPA | Senior Vice President, Chief Accounting Officer and Head of People Services |
| Linda Montella Carter | Senior Vice President and Chief Information Officer |
| Mark Elliott Boulding J.D. | Executive Vice President and Chief Legal Officer |
| Jane Baj | Vice President of Corporate Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 17, 2025 | 8-K | Current Report |
| May 16, 2025 | 144 | Filing |
| May 15, 2025 | 144 | Filing |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 6, 2025 | 10-Q | Quarterly Report |
| May 6, 2025 | 8-K | Current Report |
| May 5, 2025 | 8-K | Current Report |
| Apr 30, 2025 | ARS | Filing |
| Apr 30, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 30, 2025 | DEF 14A | Other definitive proxy statements |